Revenue Update on Bioline RX Ltd(NASDAQ:BLRX)

Bioline RX Ltd(NASDAQ:BLRX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 23, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $0.000. Analysts estimated a revenue of $10.000K. The revenues were -100% below the estimates. Earnings per share were $-0.13. The reported EPS was below estimates by -62.5%. Analysts had estimated an EPS of $-0.08.

In a different note, Rodman & Renshaw said it Initiates Coverage On Bioline RX Ltd, according to a research note issued on Feb 13, 2017. In the research note, the firm Announces the price-target to $3 per share. The shares have been rated ‘Buy’ by the firm.

Bioline RX Ltd (BLRX) made into the market gainers list on Fridays trading session with the shares advancing 0.91% or 0.01 points. Due to strong positive momentum, the stock ended at $1.1099, which is also near the day’s high of $1.11. The stock began the session at $1.1 and the volume stood at 4,06,070 shares. The 52-week high of the shares is $1.42 and the 52 week low is $0.71. The company has a current market capitalization of $69 M and it has 6,17,82,434 shares in outstanding.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics from preclinical-stage development to advanced clinical trials for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040 which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010 which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers and BL-7040 a synthetic oligonucleotide which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

Add Comment